Delphine CharvinFounder

France - ND

Delphine is an experienced and entrepreneurial C-level executive. Her previous roles include CSO of Prexton Therapeutics (acquired by Lundbeck for $1.1B), CSO at Lundbeck, CSO/CINO of Stalicla and Operating Partner of the startup studio Argobio. She has 15 years of experience working with startups, biotechs, pharma companies and VCs. Over the past 10 years, she has held co-founding and managerial positions in drug discovery and clinical development companies that have raised over €150 million.

• CEO, Co-Founder and Board Director of Elkedonia
• Previously Operating Partner of the startup studio Argobio
• Successful biotech company development from inception to exit ($1.1 billion deal)
• Venture builder: 3 Newco co-created, 2 scale-up (from preclinical to clinical stages), 1 M&A
• Drug discovery and development from target validation to preparation of Phase III clinical trial
• Preparation and initiation/completion of 9 clinical studies, including observational, Phases I, II and PET studies, in USA and in Europe (3 IND approvals)
• Management of multidisciplinary teams, in virtual or face-to-face environments, up to 30+ reports
• Consulting in drug discovery and development, scientific and business communication, project assessment and due diligences for VC, business strategy for start-up and biotech companies